【摘 要】
：
主要介绍克服酪氨酸激酶Gleevec耐药的一些进展.第一代靶点药物Gleevec耐药的主要形成机制是出现靶点点突变和基因扩增.潘景轩教授等发现了新型酪氨酸激酶抑制剂(EXEL-0862)(
【出 处】
：
华东抗肿瘤药物研究新进展与肿瘤精准治疗论坛
论文部分内容阅读
主要介绍克服酪氨酸激酶Gleevec耐药的一些进展.第一代靶点药物Gleevec耐药的主要形成机制是出现靶点点突变和基因扩增.潘景轩教授等发现了新型酪氨酸激酶抑制剂(EXEL-0862)(Blood,Leukemia,2007)、DCC-2063(PloS One,2013)、ponatinib(Mol Cancer Ther,2014;Mol Cancer,2014;Cancer Ther Biol,2014)及GZD824(JMC,2013)、S116836(Oncotarget 2014;Cancer Ther Biol,2014)能抑制突变体酪氨酸激酶的活性,并杀死耐受性白血病细胞;
其他文献
目的：阿霉素作为治疗骨肉瘤的一线化疗药物，仍因复发和转移的出现而宣告治疗失败。根据肿瘤干细胞理论，骨肉瘤干细胞的存在可能是治疗失败的关键因素，目前针对骨肉瘤化疗与肿
Background: The aim of our study is to evaluate the preliminary efficacy and side effects of paclitaxel,5-fluorouracil and leucovorin intravenous chemothera
Objectives: Unimolecular micelles were prepared by modification of polyamidoamine(PAMAM)dendrimersusing pluronic F68(PF68),which is expected to reverse mult
Objective: Most non-small cell lung cancer(NSCLC)patients responding to gefitinib harbor activating mu tations in the epidermal growth factor receptor(EGFR)
Background: Gastric cancer is the fourth most common cancer in the world.The development of both chemotherapy and targeted drugs are limited due to the comp
Background: β-elemene is a novel anticancer drug extracted from herb which has been used to target various solid tumours and Hyperthermia is an adjuvant th
Objective: Anti-PD-1/PD-L1 antibodies showed satisfactory efficacy in treating non-small-cell lung cancer.We conducted this meta-analysis to explore the adv
流行病学每年新增病例95.2万,死亡病例72.3万.亚洲胃癌发病率及死亡率居全世界首位.晚期胃癌的化疗进展(1)转移性弥漫型胃腺癌化疗:SP方案优于FP方案?S-1+顺铂对比5-FU+顺铂
细胞死亡程序受损被认为是慢性淋巴细胞性白血病(CLL)的显著特征之一,同时也是导致恶性单克隆B细胞大量累积以及化疗耐药的重要诱因.细胞有两种死亡途径:凋亡或坏死途径.最近